 Connection
Brian Sauer to Antirheumatic Agents
This is a "connection" page, showing publications Brian Sauer has written about Antirheumatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.822 |
|
|
|
-
Sauer BC, Chen W, Shen J, Accortt NA, Collier DH, Cannon GW. Potential for Major Therapeutic Changes to Produce Significant Clinical Response Across a Broad Range of Disease Activity: An Observational Study of US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 07; 73(7):964-974.
Score: 0.608
-
Sauer BC, Chen W, Xu Y, Shen J, Accortt NA, Collier DH, Cannon GW. Empirical evidence of disease activity thresholds used to indicate need for major therapeutic change in US veterans with rheumatoid arthritis. Arthritis Res Ther. 2020 10 22; 22(1):253.
Score: 0.582
-
Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer BC. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol. 2018 03; 45(3):430-436.
Score: 0.475
-
Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, Harrison DJ, Cannon GW. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 03; 69(3):313-322.
Score: 0.452
-
Lu CC, Leng J, Cannon GW, Zhou X, Egger M, South B, Burningham Z, Zeng Q, Sauer BC. The use of natural language processing on narrative medication schedules to compute average weekly dose. Pharmacoepidemiol Drug Saf. 2016 12; 25(12):1414-1424.
Score: 0.438
-
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Adv Ther. 2016 08; 33(8):1347-59.
Score: 0.431
-
Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ. 2016; 19(1):34-43.
Score: 0.410
-
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol. 2014 Oct; 41(10):1935-43.
Score: 0.379
-
Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, Caplan L, Kerr GS, Richards JS, Johnson DS, Sauer BC. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken). 2011 Dec; 63(12):1680-90.
Score: 0.314
-
Song S, England BR, Sauer B, George MD, Riley TR, Wallace B, Cannon GW, Mikuls TR, Baker JF. Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following the Release of Safety Data. Arthritis Care Res (Hoboken). 2024 04; 76(4):463-469.
Score: 0.182
-
Baker JF, England BR, George MD, Wysham K, Johnson T, Lenert A, Kunkel G, Sauer B, Duryee MJ, Monach P, Kerr G, Reimold A, Thiele GM, Mikuls TR. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022 08; 55:152003.
Score: 0.161
-
Johnson TM, Sayles HR, Baker JF, George MD, Roul P, Zheng C, Sauer B, Liao KP, Anderson DR, Mikuls TR, England BR. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021 11; 80(11):1385-1392.
Score: 0.152
-
Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm. 2019 Nov; 25(11):1218-1228.
Score: 0.136
-
Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. Arthritis Care Res (Hoboken). 2019 10; 71(10):1326-1335.
Score: 0.134
-
Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer BC. Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. J Rheumatol. 2020 01; 47(1):42-49.
Score: 0.130
-
Stever JR, Cannon GW, Teng CC, Accortt NA, Collier DH, Sauer BC. Utility of administrative and clinical data to predict major change in medical treatment in US Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry. Clin Exp Rheumatol. 2019 Jul-Aug; 37(4):552-560.
Score: 0.127
-
McCulley CB, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2019 May-Jun; 37(3):422-428.
Score: 0.127
-
England BR, Sayles H, Michaud K, Thiele GM, Poole JA, Caplan L, Sauer BC, Cannon GW, Reimold A, Kerr GS, Baker JF, Mikuls TR. Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. Clin Rheumatol. 2018 Nov; 37(11):2907-2915.
Score: 0.126
-
George MD, Sauer BC, Teng CC, Cannon GW, England BR, Kerr GS, Mikuls TR, Baker JF. Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis. J Rheumatol. 2019 04; 46(4):343-350.
Score: 0.126
-
Baker JF, Sauer B, Teng CC, George M, Cannon GW, Ibrahim S, Cannella A, England BR, Michaud K, Caplan L, Davis LA, O'Dell J, Mikuls TR. Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. J Clin Rheumatol. 2018 Jun; 24(4):203-209.
Score: 0.123
-
Baker JF, Sauer BC, Cannon GW, Teng CC, Michaud K, Ibrahim S, Jorgenson E, Davis L, Caplan L, Cannella A, Mikuls TR. Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 08; 68(8):1818-27.
Score: 0.109
-
England BR, Campany M, Sayles H, Roul P, Yang Y, Ganti AK, Sokolove J, Robinson WH, Reimold AM, Kerr GS, Cannon GW, Sauer BC, Baker JF, Thiele GM, Mikuls TR. Associations of serum cytokines and chemokines with the risk of incident cancer in a prospective rheumatoid arthritis cohort. Int Immunopharmacol. 2021 Aug; 97:107719.
Score: 0.038
-
Baker JF, England BR, George M, Cannon G, Sauer B, Ogdie A, Hamilton BC, Hunter C, Duryee MJ, Thiele G, Mikuls TR. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. Ann Rheum Dis. 2021 05; 80(5):566-572.
Score: 0.037
-
England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, Sauer BC, Solow EB, Reimold AM, Kerr GS, Schwab P, Baker JF, Mikuls TR. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):36-45.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|